Adaptimmune Therapeutics plc (ADAP) has an overall financial health rating of C with a composite score of 0 out of 5.
This suggests the company faces some financial challenges worth monitoring. Rating as of 2025-10-27.
| Date | Rating | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-10-27 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-10-24 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-10-23 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-10-22 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-10-21 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-10-20 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-10-17 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-10-16 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-10-15 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-10-14 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-10-13 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2025-10-10 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 |
